Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Evaluation of risk factors for ofloxacin – resistant infections in urinary tract infections

  • At: 2009 FIP Congress in Istanbul (Turkey)
  • Type: Poster
  • By: ACIU, Mariana (University of Medicine and Pharmacy, Craiova, Romania)
  • Co-author(s): Calina, Daniela (University of Medicine and Pharmacy, CRAIOVA, Romania)
    Chiutu, Luminita (University of Medicine and Pharmacy, CRAIOVA, Romania)
    Mitrut, Paul (University of Medicine and Pharmacy, CRAIOVA, Romania)
    Georgescu, Cristian (University of Medicine and Pharmacy, CRAIOVA, Romania)
    Calina, Vivi (University of Medicine and Pharmacy, CRAIOVA, Romania)
  • Abstract:

    Objectives: The study was undertaken to assess the safety and efficacy of intravenous Ofloxacin (Tarivid, Avensis Pharma) and oral Ofloxacin (Ofloxacin, Antibiotice Iasi) in the treatment of moderate-to-severe urinary tract infections (UTI), and to identify risk factors for acquiring UTI caused by Ofloxacin - resistant germs.

    Materials and..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses